Literature DB >> 1506892

Insulin and insulin-like growth factors in central nervous system tumors. Part V: Production of insulin-like growth factors I and II in vitro.

R P Glick1, T G Unterman, M Van der Woude, L Z Blaydes.   

Abstract

The authors have previously reported the presence of insulin-like growth factor (IGF) receptors in central nervous system (CNS) tumors and the production of IGF's and their binding proteins by CNS tumors in situ. This study was designed to investigate whether CNS tumor cells are capable of autocrine secretion of IGF-I and IGF-II in vitro. Production of IGF's was studied by specific radioimmunoassay of tumor-cell-conditioned serum-free media from 34 CNS tumors: 12 gliomas, 12 meningiomas, and 10 miscellaneous tumors. Normal human serum and cerebrospinal fluid served as controls. Insulin-like growth factor I was detected in five of 12 meningiomas but in none of the gliomas studied. In contrast, IGF-II was detected in four of 12 gliomas and in six of 11 meningiomas studied. Four miscellaneous tumors produced IGF-I and/or IGF-II. These results suggest that CNS tumors differentially produce IGF-I and IGF-II in vitro. Preferential production of IGF's may be an important marker of the tumor-cell differentiation or malignancy and may be useful as a clinical diagnostic tool. These results add further support to the concept that IGF's may play a role in the regulation of the behavior of CNS tumors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1506892     DOI: 10.3171/jns.1992.77.3.0445

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  9 in total

Review 1.  Regulation of insulin-like growth factors by antiestrogen.

Authors:  R Winston; P C Kao; D T Kiang
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

2.  Effects of growth factors and basement membrane proteins on the phenotype of U-373 MG glioblastoma cells as determined by the expression of intermediate filament proteins.

Authors:  S Sultana; R Zhou; M S Sadagopan; O Skalli
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

Review 3.  Insulin-like growth factors in central nervous system tumors.

Authors:  R P Glick; T Lichtor; T G Unterman
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

4.  Inhibition of intracerebral glioblastoma growth by targeting the insulin-like growth factor 1 receptor involves different context-dependent mechanisms.

Authors:  Martin Zamykal; Tobias Martens; Jakob Matschke; Hauke S Günther; Annegret Kathagen; Alexander Schulte; Regina Peters; Manfred Westphal; Katrin Lamszus
Journal:  Neuro Oncol       Date:  2014-12-27       Impact factor: 12.300

5.  Biphasic effects of suramin on 125I-epidermal growth factor binding to human meningiomas.

Authors:  K Tsutsumi; N Kitagawa; M Niwa; S Yamaga; H Khalid; K Taniyama; A Himeno; S Shibata
Journal:  Cell Mol Neurobiol       Date:  1993-12       Impact factor: 5.046

Review 6.  The biology of meningiomas.

Authors:  I E McCutcheon
Journal:  J Neurooncol       Date:  1996-09       Impact factor: 4.130

7.  Investigation of immunosuppressive mechanisms in a mouse glioma model.

Authors:  Alexander Ksendzovsky; Douglas Feinstein; Ryan Zengou; Anthony Sharp; Paul Polak; Terry Lichtor; Roberta P Glick
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

8.  Gene therapy of murine teratocarcinoma: separate functions for insulin-like growth factors I and II in immunogenicity and differentiation.

Authors:  J Trojan; T R Johnson; S D Rudin; B K Blossey; K M Kelley; A Shevelev; F W Abdul-Karim; D D Anthony; M L Tykocinski; J Ilan
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

9.  Histamine-stimulated expression of insulin-like growth factors in human glioma cells.

Authors:  L T Van der Ven; S C Van Buul-Offers; T Gloudemans; P J Roholl; J S Sussenbach; W Den Otter
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.